Zentalis Pharmaceuticals (ZNTL) Long-Term Investments (2021 - 2024)

Zentalis Pharmaceuticals' Long-Term Investments history runs 4 years deep, the most recent figure standing at $349.9 million for Q3 2024.

• On a quarterly basis, Long-Term Investments changed N/A year-over-year to $349.9 million in Q3 2024; TTM through Sep 2024 was $349.9 million, a N/A change from a year earlier, with the FY2023 full-year figure at $454.9 million, up 2044.35% from the prior year.
• Long-Term Investments declined to $349.9 million in Q3 2024 per ZNTL's latest filing, from $389.4 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $454.9 million in Q4 2023 and bottomed at $18.9 million in Q1 2023.
• The 4-year median for Long-Term Investments is $37.5 million (2021), against an average of $168.8 million.
• Across the five-year window, Long-Term Investments sank 47.12% in 2023 and jumped 2287.81% in 2024, its largest moves.
• Year by year, Long-Term Investments stood at $37.5 million in 2021, then slumped by 43.42% to $21.2 million in 2022, then surged by 2044.35% to $454.9 million in 2023, then fell by 23.07% to $349.9 million in 2024.
• Per Business Quant, the three latest ZNTL Long-Term Investments figures stand at $349.9 million (Q3 2024), $389.4 million (Q2 2024), and $451.4 million (Q1 2024).